SNDXSyndax Pharmaceuticals Inc
Pharmaceutical Preparations
- Revenue
- $172M
- 628% YoY
- Operating margin
- -158.4%
- 89% YoY
- EBITDA
- −$267M
- 19% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired28% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $140M | $0 | $0 | $24M | $172M | 628% |
| Operating income | $26M | −$152M | −$230M | −$340M | −$273M | 20% |
| Net income | $25M | −$149M | −$209M | −$319M | −$285M | 10% |
| Operating cash flow | $29M | −$134M | −$161M | −$275M | −$323M | 17% |
| Capex | $129K | $0 | $0 | $0 | $187K | |
| Stock-based comp | $13M | $16M | $31M | $43M | $48M | 10% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $114K · 1
- Net
- −$114K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 94 | 125 |
| FY2024 | — | — | 59 | 93 |
| FY2023 | — | — | 97 | 94 |
| FY2022 | — | — | 114 | 90 |
| FY2021 | — | — | 98 | 100 |